Clinical Trial Update: A Study to Assess Biomarkers Impact on Participants Response to Erlotinib Treatment for First-line Non-Small Cell Lung Cancer With Endothelial Growth Factor Receptor (EGFR) Activating Mutations [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating whether biomarkers influence response to Erlotinib as first-line therapy in EGFR-mutant non-small cell lung cancer, with results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ERLOTINIB (Erlotinib)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Carcinoma，Non-Small-Cell Lung | Phase 2 | Status: COMPLETED | Results posted: 2017-04-13